| Variables |
Patients with LDH<246
Group 1
N=102% |
Patients with LDH≥246
Group 2
N=54% |
Total (156)
N% |
Median age
years (min-max) |
26.5 (13-57) |
25.5 (15-52) |
26.0 (13-57) |
Gender
female
male |
42 (41.2)
60 (58.8) |
21 (38.9)
33 (61.1) |
63 (40.3)
93 (59.7) |
Diagnosis
AML
ALL
CML
AA
Lymphoma
Others |
43 (42.2)
25 (24.5)
4 (3.9)
14 (13.7)
10 (9.8)
6 (5.9) |
23 (42.6)
13 (24.1)
2 (3.7)
4 (7.4)
6 (11.1)
6 (11.1) |
68(43.5)
38 (24.3)
6 (3.8)
18 (11.5)
16 (10.3)
12 (7.6) |
Acute GVHD
Yes
No |
20(19.6)
82(80.4) |
13(24.1)
41(75.9) |
33(21.1)
123(78.9) |
Chronic GVHD
Yes
No |
38(37.3)
64(62.7) |
20(37.0)
34(63.0) |
58(37.1)
98(62.9) |
Disease status at tx
CR1
CR2
Active disease |
90(88.3)
4(3.9)
8(7.8) |
45(83.3)
3(5.6)
6(11.1) |
135(86.5)
7(4.6)
14(8.9) |
| CD34+ (106/kg) |
|
|
|
Preparative regimen
Bu/Cy
TBI/Cy
ATG/Flu/Cy
ATG/Flu/Bu
Flu/Cy
Others |
52(51.0)
14(13.7)
12(11.8)
3(2.9)
9(8.8)
12(11.8) |
25(46.3)
7(13.0)
4(7.4)
6(11.1)
3(5.6)
9(7.6) |
77(49.3)
21(13.5)
16(10.3)
9(5.7)
12(7.7)
21(13.5) |
HLA match
full-match
≥ 1 miss-match
Unrelated |
90(88.2)
11(10.8)
1(1.0) |
44(81.5)
8(14.8)
2(3.7) |
134(85.9)
19(12.1)
3(2.0) |
Median interval to tx (months)
<12 months
>12 months |
69(67.6)
33(32.4) |
37(68.5)
17(31.5) |
106(78.0)
50(22.0) |
Graft source
PBSC
BM |
102 (100)
0 |
54 (100)
0 |
156(100)
0 |
| Gender match
matched
mismatched |
76(74.5)
26(25.5) |
35(64.8)
19(35.2) |
111(71.1)
45(28.9) |
